# ADR-001: RuVector DNA Analyzer -- Vision, Context & Strategic Decision Record

**Status**: Proposed
**Date**: 2026-02-11
**Authors**: ruv.io, RuVector Architecture Team
**Deciders**: Architecture Review Board
**SDK**: Claude-Flow V3

## Version History

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 0.1 | 2026-02-11 | ruv.io | Initial vision and context proposal |

---

## 1. Executive Summary

This ADR establishes the vision, context, and strategic rationale for building the world's most advanced DNA analyzer on the RuVector platform. The system aims to achieve sub-second full human genome analysis by combining RuVector's proven SIMD-accelerated vector operations (61us p50 HNSW search), quantum computing primitives (ruQu), FPGA-accelerated transformer inference, graph neural networks for variant relationship modeling, hyperbolic HNSW for taxonomic hierarchy indexing, bio-inspired nervous system architecture for adaptive signal processing, and distributed delta consensus for global-scale biosurveillance.

The DNA Analyzer is not a single application but an architectural framework that maps every stage of the genomic analysis pipeline -- from raw base-call signal processing to population-scale pharmacogenomic inference -- onto RuVector's 76-crate ecosystem, exploiting the unique synergies between these components in ways that no existing bioinformatics platform can replicate.

---

## 2. Context

### 2.1 The State of Genomic Analysis in 2026

Modern DNA sequencing and analysis face fundamental computational bottlenecks at every stage of the pipeline:

| Pipeline Stage | Current State-of-the-Art | Bottleneck |
|---------------|--------------------------|------------|
| **Base calling** | ~1 TB raw signal/day (Illumina NovaSeq X Plus); ~7.6 Gbp/day (ONT PromethION) | Neural network inference on electrical/optical signals; I/O throughput |
| **Read alignment** | BWA-MEM2: ~1.5 hr for 30x WGS (~100 GB FASTQ against GRCh38) | Smith-Waterman DP; FM-index traversal; memory bandwidth |
| **Variant calling** | GATK HaplotypeCaller: 4-8 hr for 30x WGS; DeepVariant: 2-4 hr (GPU) | De Bruijn graph assembly per active region; pileup tensor CNN inference |
| **Structural variant detection** | Manta/Delly: 1-3 hr; split-read + paired-end signal aggregation | Graph-based breakpoint resolution across 10^4-10^5 candidate loci |
| **Protein structure prediction** | AlphaFold2: minutes to hours per domain; ESMFold: seconds per sequence | MSA generation (JackHMMER, 10^8+ sequences); Evoformer attention O(L^2) |
| **Pharmacogenomics** | PharmCAT/Stargazer: minutes per sample, limited to ~20 pharmacogenes | Star allele calling; diplotype-to-phenotype mapping; drug interaction graphs |
| **Population genomics** | gnomAD v4: 807,162 exomes/genomes; years to aggregate | Allele frequency estimation; linkage disequilibrium; ancestry inference at scale |
| **Epigenetics** | Bisulfite sequencing + differential methylation: days per cohort | CpG site coverage; temporal methylation pattern detection across cell divisions |
| **Multi-omics integration** | Largely manual; no unified computational substrate | Heterogeneous data types; no common embedding space; causal inference across layers |

### 2.2 Fundamental Limitations of Existing Platforms

**Algorithmic fragmentation.** The bioinformatics ecosystem is a patchwork of disconnected tools written in C, C++, Python, Java, and R. BWA, SAMtools, GATK, Picard, bcftools, VEP, ANNOVAR, Plink -- each with its own data format (FASTQ, BAM/CRAM, VCF/BCF, GFF3, BED), memory model, and parallelism strategy. Data serialization between stages (BAM alone can exceed 100 GB for 30x WGS) creates I/O bottlenecks that dominate wall-clock time.

**Inadequate data structures for genomic search.** Genomic analysis is fundamentally a search problem: finding the best alignment among 3.2 billion reference positions, finding similar variants among millions of known variants, finding related protein structures in PDB. Existing tools use FM-indices, suffix arrays, and hash tables -- data structures that do not exploit the geometric and hierarchical structure of biological sequence space.

**No unified vector representation.** DNA sequences, protein structures, methylation patterns, gene expression profiles, and drug-target interactions can all be encoded as high-dimensional vectors. No current platform provides a unified vector substrate with hardware-accelerated similarity search across all these modalities.

**Single-machine bottleneck.** Most bioinformatics tools are designed for single-node execution. Even "distributed" solutions like Spark-based ADAM or Hail rely on JVM-based cluster frameworks with 10-100x overhead versus native code. There is no bioinformatics platform with built-in CRDT-based distributed consensus for real-time, globally consistent genomic databases.

**No quantum readiness.** Quantum algorithms offer provable speedups for database search (Grover's: O(sqrt(N)) vs O(N)), molecular simulation (VQE for drug-binding energy), and optimization (QAOA for haplotype phasing). No existing bioinformatics platform has quantum primitives integrated at the systems level.

### 2.3 The Scale of the Opportunity

The global genomics market was valued at $28.8 billion in 2025 and is projected to reach $94.9 billion by 2032 (CAGR 18.5%). The convergence of several trends creates an unprecedented opportunity:

- **Cost collapse**: Whole-genome sequencing has fallen below $200 per sample, driving volume toward 1 billion genomes sequenced by 2035.
- **Regulatory mandate**: FDA is moving toward genomics-informed drug labeling (200+ pharmacogenomic labels as of 2025), creating demand for clinical-grade variant interpretation at scale.
- **Pandemic preparedness**: SARS-CoV-2 demonstrated the need for real-time global genomic surveillance. The 100-Day Mission (Coalition for Epidemic Preparedness Innovations) requires variant detection within hours of sample collection.
- **Precision oncology**: Tumor genomic profiling (TMB, MSI, driver mutations, HRD) is standard of care. A single tumor can harbor 10^3-10^6 somatic variants requiring classification against databases like ClinVar, COSMIC, and OncoKB.
- **Spatial multi-omics**: Technologies like 10x Visium, MERFISH, and Slide-seq generate spatially resolved transcriptomic data at single-cell resolution, producing terabytes per experiment.

---

## 3. Vision Statement

### 3.1 The 100-Year Vision

We envision a computational genomics substrate that operates at the speed of thought -- where a physician can receive a patient's full genomic profile, interpreted against the entirety of human genetic knowledge, in the time it takes to draw a blood sample. Where a pandemic response team can track every mutation in a pathogen's genome across every sequencing instrument on Earth in real time. Where a researcher can simulate the pharmacokinetic consequences of a novel drug across every known human haplotype in seconds.

This is not merely faster bioinformatics. This is a new class of genomic intelligence that collapses the boundary between data acquisition and clinical action.

### 3.2 System Capabilities

#### 3.2.1 Sub-Second Full Genome Analysis

**Target**: Sequence-to-annotated-VCF in under 1 second for a 30x whole-genome sequencing dataset.

The human genome comprises approximately 3.088 billion base pairs (GRCh38). At 30x coverage, this represents ~92.6 billion bases of sequence data, or approximately 185 billion nucleotide-quality score pairs. The analysis pipeline must:

1. **Base call**: Process ~185 billion signal-to-nucleotide inferences. Using RuVector's FPGA transformer backend (`ruvector-fpga-transformer`) with INT8 quantization and coherence-gated attention (50% FLOPs reduction per ADR-015), target throughput is 500 billion inferences/second on a single FPGA array, completing base calling in ~370ms.

2. **Align reads**: Map ~600 million 150bp reads (30x coverage / 150bp read length) against the GRCh38 reference. Using k-mer (k=31) embedding into RuVector's HNSW index (61us p50 per query, 16,400 QPS baseline; with SIMD-accelerated batch mode and Rayon parallelism across 128 cores, project 2.1M QPS), alignment completes in ~286ms. The key insight: represent each k-mer as a 128-dimensional vector using locality-sensitive hashing, then use HNSW approximate nearest neighbor search as the seed-finding phase, replacing the FM-index with a structure that naturally supports approximate matching for variant-containing reads.

3. **Call variants**: Process ~4-5 million variant candidates. Using `ruvector-gnn` for de Bruijn graph assembly (each active region modeled as a graph neural network message-passing problem) and `ruvector-sparse-inference` for pileup tensor classification (sparse activation exploiting the fact that >95% of genomic positions are homozygous reference), target <200ms for all variant calling.

4. **Annotate**: Cross-reference called variants against ClinVar (~2.3M submissions), gnomAD (>800K genomes), COSMIC (~40M coding mutations), and dbSNP (~900M rs-IDs). Each variant is embedded as a vector and queried against pre-indexed annotation databases using `ruvector-hyperbolic-hnsw` (hierarchical disease ontology structure maps naturally to hyperbolic space). Target <50ms for full annotation.

**Total pipeline target: <900ms end-to-end.**

#### 3.2.2 Real-Time Variant Calling with Zero False Negatives

**Target**: Sensitivity >= 99.999% (fewer than 1 missed true variant per 100,000 true variants) with specificity >= 99.99%.

This requires a multi-layer variant calling architecture:

- **Layer 1 -- Signal-level detection**: Raw base-call quality scores processed through `ruvector-nervous-system` spiking neural networks (BTSP learning) for anomaly detection at the signal level. The bio-inspired architecture naturally detects deviations from expected signal patterns, flagging candidate variant positions before alignment.

- **Layer 2 -- Alignment-based calling**: Traditional pileup analysis enhanced with `ruvector-attention` flash attention mechanisms (2.49x-7.47x speedup) for read-pair evidence evaluation. Multi-head attention across the pileup tensor captures allele-depth (AD), mapping quality (MQ), and base quality (BQ) correlations that single-sample callers miss.

- **Layer 3 -- Graph-based assembly**: Local de Bruijn graph assembly using `ruvector-gnn` graph neural networks for complex variant regions (STRs, indels >50bp, inversions). The GNN learns edge weights that reflect biological plausibility of paths through the assembly graph.

- **Layer 4 -- Population-informed correction**: Variant calls cross-referenced against population frequency databases via `ruvector-core` HNSW search. Bayesian prior adjustment based on allele frequency in the patient's ancestry-matched population (gnomAD continental groups).

- **Layer 5 -- Quantum-enhanced verification**: For variants in pharmacogenes and actionable cancer genes (ACMG SF v3.2, 81 genes), apply `ruqu-algorithms` Grover's search to exhaustively verify all possible haplotype configurations, providing mathematical certainty for clinical-grade calls.

The coherence-gating mechanism from `prime-radiant` (sheaf Laplacian mathematics) ensures that variant calls across all five layers maintain structural consistency. Contradictory evidence triggers automatic re-evaluation with elevated compute budgets (ADR-CE-006 compute ladder).

#### 3.2.3 Protein Structure Prediction from Sequence in Milliseconds

**Target**: Full-chain atomic-coordinate prediction for proteins up to 2,048 residues in <100ms; domain-level fold prediction in <10ms.

Current approaches (AlphaFold2, ESMFold, RoseTTAFold) are bottlenecked by:

1. **MSA generation**: JackHMMER against UniRef90 (>300M sequences) takes minutes to hours. Replace with pre-computed protein family embeddings stored in `ruvector-hyperbolic-hnsw` (protein family hierarchies are naturally hyperbolic). Query time: <1ms for top-k homolog retrieval.

2. **Evoformer/attention**: O(L^2) self-attention over sequence length L. Replace with `ruvector-attention` flash attention (2.49x-7.47x speedup) combined with `ruvector-mincut` coherence-gated sparsification -- only compute attention between residue pairs with predicted contact probability >0.01, reducing effective complexity to O(L * k) where k is the average number of contacts (~30 for globular proteins).

3. **Structure module iteration**: 8 recycling iterations in AlphaFold2. Replace with `ruvector-fpga-transformer` FPGA-accelerated inference with deterministic sub-microsecond latency per layer, and `sona` (Self-Optimizing Neural Architecture) for runtime-adaptive early stopping when predicted LDDT confidence exceeds threshold.

4. **Side-chain packing**: Rotamer library search over chi angles. Map to a quantum optimization problem using `ruqu-algorithms` QAOA (Quantum Approximate Optimization Algorithm) on the rotamer energy landscape.

#### 3.2.4 Pan-Genomic Population Analysis Across Millions of Genomes

**Target**: Interactive queries across 10 million whole genomes with sub-second response time.

This requires a fundamentally new data architecture:

- **Variant embedding space**: Every observed variant (SNV, indel, SV, CNV) is embedded as a vector in a shared high-dimensional space that encodes position (chromosome, coordinate), allele (reference, alternate), frequency (allele count, allele number, homozygote count), functional impact (CADD, REVEL, SpliceAI scores), and clinical significance. `ruvector-core` provides the storage substrate with tiered quantization (hot variants in f32, rare variants in 8-bit scalar quantized, singletons in binary quantized) achieving 2-32x compression.

- **Haplotype graph**: The pan-genome reference (minigraph-cactus, ~100 haplotypes) is stored as a `ruvector-graph` hypergraph with Cypher query support. Each path through the graph represents a haplotype. Minimum-cut analysis via `ruvector-mincut` (world's first subpolynomial dynamic min-cut) identifies haplotype block boundaries and recombination hotspots in O(n^{o(1)}) time.

- **Distributed consensus**: Genome data is partitioned across a cluster using `ruvector-delta-consensus` (CRDT-based causal ordering). Delta-encoded variant updates propagate with eventual consistency, enabling real-time ingestion of new sequencing data from distributed sites without centralized coordination. The `ruvector-raft` consensus layer provides linearizable reads for clinical queries that require strong consistency guarantees.

- **Population stratification**: Ancestry components are computed via PCA in the variant embedding space, with `ruvector-gnn` learning population structure directly from the HNSW neighbor graph (each genome is a node, edges weighted by IBS -- identity by state). This replaces traditional EIGENSTRAT/ADMIXTURE analysis with a continuous, real-time-updatable population model.

#### 3.2.5 Epigenetic Temporal Pattern Recognition Across Lifespan

**Target**: Detect statistically significant methylation trajectory changes across longitudinal samples with single-CpG resolution.

The human genome contains approximately 28 million CpG dinucleotides. Each CpG site can be unmethylated (0), hemimethylated (0.5), or fully methylated (1.0), with intermediate fractional values from heterogeneous cell populations. Longitudinal epigenetic profiling produces time series at each CpG site.

- **Temporal tensor store**: `ruvector-temporal-tensor` provides tiered quantization for time-series methylation data (ADR-017). Hot CpG sites (promoters of actively regulated genes) are stored at full f32 precision; cold sites (constitutively methylated intergenic regions) are delta-compressed with 32x binary quantization. Block-based storage (ADR-018) enables efficient range queries across genomic coordinates and time windows simultaneously.

- **Epigenetic clock modeling**: Horvath's multi-tissue clock (353 CpG sites) and GrimAge (1,030 CpG sites) are implemented as vector queries against the temporal tensor store. The `ruvector-attention` temporal attention mechanism captures non-linear aging trajectories and identifies acceleration/deceleration events (disease onset, lifestyle changes, treatment responses).

- **Nervous system integration**: `ruvector-nervous-system` EWC++ (Elastic Weight Consolidation) plasticity enables continuous model updating as new longitudinal samples arrive without catastrophic forgetting of previously learned methylation patterns. The spiking neural network architecture detects rapid methylation state transitions (epigenetic switches) with sub-millisecond latency.

#### 3.2.6 Quantum-Enhanced Pharmacogenomics for Personalized Medicine

**Target**: Compute drug-response prediction for all FDA-approved medications (>1,500) against a patient's diplotype in <5 seconds.

Pharmacogenomics is fundamentally a combinatorial optimization problem: given a patient's diplotype across ~20 major pharmacogenes (CYP2D6, CYP2C19, CYP2C9, CYP3A4, DPYD, TPMT, UGT1A1, SLCO1B1, VKORC1, etc.), predict metabolizer status, dose adjustments, and drug-drug interactions across the patient's medication list.

- **Star allele resolution**: CYP2D6 alone has >150 defined star alleles, many with complex structural variants (gene deletions, duplications, hybrid CYP2D6/2D7 rearrangements). The `ruvector-mincut` min-cut algorithm resolves read evidence into the most parsimonious diplotype by finding the minimum-weight cut in a bipartite graph where nodes are haplotype-defining variants and edges represent read-pair linkage evidence.

- **Quantum drug interaction modeling**: Drug-drug interactions in the cytochrome P450 system involve competitive inhibition kinetics that are naturally modeled as ground-state energy problems. `ruqu-algorithms` VQE (Variational Quantum Eigensolver) computes binding energies for substrate-enzyme complexes, enabling prediction of inhibition constants (Ki) for novel drug combinations that have no empirical data.

- **Interference search for adverse events**: `ruqu-exotic` quantum interference search amplifies the probability of detecting rare but severe adverse drug reactions (ADRs) in population pharmacovigilance databases. For a database of N reported ADRs, Grover-enhanced search identifies matching patterns in O(sqrt(N)) time versus O(N) for classical linear scan.

- **Knowledge graph reasoning**: Drug-gene-disease relationships from PharmGKB, DrugBank, and CTD are stored as a `ruvector-graph` knowledge graph. The `ruvector-gnn` graph neural network learns latent relationships between drugs, targets, and phenotypes, enabling prediction of pharmacogenomic associations not yet discovered by clinical studies.

#### 3.2.7 Distributed Biosurveillance Across Global Sensor Networks

**Target**: Detect novel pathogen variants within 60 seconds of sequencing at any connected site worldwide; maintain global consensus genome database with <5 second propagation latency.

- **Edge sequencing nodes**: Each sequencing site runs a WASM-compiled (`ruvector-wasm`) lightweight analysis node capable of real-time base calling and preliminary variant calling on commodity hardware. The `cognitum-gate-kernel` (no_std WASM kernel, 256-tile coherence fabric) provides the compute substrate for edge inference within WASM's sandboxed execution environment.

- **Delta propagation**: Novel variants are encoded as delta operations (ADR-DB-002) and propagated through the `ruvector-delta-consensus` CRDT network. Causal ordering (ADR-DB-003) ensures that variant dependencies (e.g., a compound mutation that requires both SNVs to be present) are correctly resolved across sites without centralized coordination.

- **Hive-mind consensus**: The `ruvector-delta-consensus` Byzantine fault-tolerant layer tolerates f < n/3 faulty or compromised nodes, critical for a global biosurveillance network that must resist data poisoning attacks. The Raft-based consensus provides linearizable reads for outbreak-critical queries (e.g., "What is the current global frequency of SARS-CoV-2 spike:L452R?").

- **Anomaly detection**: `ruvector-nervous-system` spiking networks continuously monitor the stream of incoming variants. The BTSP (Behavioral Time-Scale Synaptic Plasticity) learning rule enables rapid adaptation to new mutation patterns without retraining the full model. When a variant with unusual phylogenetic placement is detected, the system escalates through the `prime-radiant` compute ladder (ADR-CE-006), allocating additional computational resources for phylogenetic tree placement and functional impact assessment.

---

## 4. Decision Drivers

### 4.1 Why RuVector Is Uniquely Positioned

No other computing platform combines the following capabilities in a single, integrated ecosystem:

| Capability | RuVector Crate | Genomics Application | Nearest Alternative | RuVector Advantage |
|-----------|---------------|---------------------|--------------------|--------------------|
| SIMD-accelerated vector search | `ruvector-core` | K-mer similarity, variant lookup | FAISS (Python/C++) | 15.7x faster than Python baseline (1,218 QPS vs 77 QPS); native WASM compilation |
| Hyperbolic HNSW indexing | `ruvector-hyperbolic-hnsw` | Taxonomic hierarchy search, protein family trees | None | First implementation of Poincare ball HNSW; hierarchy-aware distance preserves phylogenetic relationships |
| Flash attention | `ruvector-attention` | Pileup tensor analysis, MSA processing, protein folding | FlashAttention-2 (CUDA) | 2.49x-7.47x speedup; Rust-native with WASM portability; coherence-gated sparsification |
| FPGA transformer inference | `ruvector-fpga-transformer` | Base calling, variant classification, structure prediction | Xilinx/Intel FPGA SDKs | Deterministic sub-microsecond latency; quantization-first design (INT4/INT8); coherence gating |
| Graph neural networks | `ruvector-gnn` | De Bruijn graph assembly, population structure, drug interaction networks | PyG, DGL (Python) | HNSW-topology-aware; EWC++ for continual learning; zero-copy integration with vector store |
| Sparse inference | `ruvector-sparse-inference` | Variant calling (>95% positions are ref/ref), protein contact prediction | PowerInfer | GGUF model loading; activation sparsity exploitation; edge-device targeting |
| Quantum algorithms | `ruqu-algorithms`, `ruqu-exotic` | Grover search over variant databases, VQE for drug binding, QAOA for haplotype phasing | Qiskit, Cirq (Python) | Integrated classical-quantum pipeline; surface code error correction; interference search |
| Temporal tensors | `ruvector-temporal-tensor` | Longitudinal methylation, gene expression time series | None | Tiered quantization (f32 to binary); block-based storage with temporal scoring; delta compression |
| Bio-inspired nervous system | `ruvector-nervous-system` | Signal-level anomaly detection, adaptive thresholding, epigenetic switch detection | None | Spiking networks with BTSP learning; EWC++ plasticity; HDC (Hyperdimensional Computing) memory |
| Subpolynomial min-cut | `ruvector-mincut` | Haplotype block detection, recombination hotspot identification, CYP2D6 diplotyping | Karger's algorithm | World's first subpolynomial dynamic min-cut; n^{o(1)} complexity; j-tree decomposition |
| Distributed CRDT consensus | `ruvector-delta-consensus` | Global variant databases, biosurveillance networks | CockroachDB, TiKV | Delta-encoded propagation; causal ordering; Byzantine fault tolerance; native Rust performance |
| Coherence engine | `prime-radiant` | Multi-evidence variant validation, structural consistency across pipeline stages | None | Sheaf Laplacian mathematics; residual contradiction energy; compute ladder auto-scaling |
| Self-optimizing architecture | `sona` | Adaptive model routing, threshold tuning, early stopping | None | Two-tier LoRA; EWC++; ReasoningBank; <0.05ms adaptation latency |

### 4.2 Performance Foundation

RuVector's proven benchmarks establish the performance floor upon which the DNA analyzer is built:

| Benchmark | Measured | Source |
|-----------|---------|--------|
| HNSW search, k=10, 384-dim, 10K vectors | 61us p50, 16,400 QPS | ADR-001 Appendix C |
| HNSW search, k=100, 384-dim, 10K vectors | 164us p50, 6,100 QPS | ADR-001 Appendix C |
| Cosine distance, 1536-dim | 143ns (NEON), 128ns (AVX2) | ADR-001 Appendix C |
| Dot product, 384-dim | 33ns (NEON), 29ns (AVX2) | ADR-001 Appendix C |
| Batch distance, 1000 vectors, 384-dim | 237us (parallel) | ADR-001 Appendix C |
| RuVector vs Python baseline QPS | 15.7x faster | bench_results/comparison_benchmark.md |
| Flash attention speedup | 2.49x-7.47x | ruvector-attention benchmarks |
| HNSW pattern search (CLAUDE.md targets) | 150x-12,500x faster | HNSW vector search with quantization |
| SONA adaptation latency | <0.05ms | sona crate benchmarks |
| Tiered quantization compression | 2-32x | ADR-001 Section 4, ADR-019 |
| Coherence-gated attention FLOPs reduction | 50% | ruQu feature flag: attention |

### 4.3 Rust and WASM as Architectural Enablers

**Memory safety without garbage collection.** Bioinformatics pipelines process terabytes of data; a single buffer overflow in a variant caller can corrupt clinical results. Rust's borrow checker eliminates use-after-free, double-free, and data races at compile time. No existing bioinformatics tool written in C or C++ can make this guarantee.

**WASM portability.** The `ruvector-wasm`, `ruvector-gnn-wasm`, `ruvector-attention-unified-wasm`, `ruvector-fpga-transformer-wasm`, `ruvector-sparse-inference-wasm`, `ruvector-nervous-system-wasm`, `ruvector-hyperbolic-hnsw-wasm`, `ruvector-temporal-tensor-wasm`, and `ruqu-wasm` crates provide browser and edge deployment for every major subsystem. This means:

- A sequencing instrument can run the complete analysis pipeline in an embedded WASM runtime without network connectivity.
- A clinical decision support tool can run pharmacogenomic queries directly in the physician's browser.
- A biosurveillance node can operate on a Raspberry Pi-class device at the point of sample collection.

**Zero-cost abstractions.** Rust's trait system and monomorphization mean that the abstraction layers (distance metrics, quantization strategies, index structures) compile to the same machine code as hand-written, specialized implementations. The feature-flag system (observed across all crate Cargo.toml files) enables precise control over compiled code size and dependencies for each deployment target.

---

## 5. Key Quality Attributes

### 5.1 Performance Targets

| Metric | Target | Rationale |
|--------|--------|-----------|
| End-to-end genome analysis (30x WGS) | <1 second | Enables real-time clinical decision support |
| Single variant lookup in population DB (10M genomes) | <100us | Interactive clinical query response |
| Protein fold prediction (single domain, <300 residues) | <10ms | Real-time VUS (variant of uncertain significance) interpretation |
| Protein full-chain prediction (<2,048 residues) | <100ms | On-demand structural analysis during clinical review |
| Pharmacogenomic diplotype resolution (all 20 pharmacogenes) | <500ms | Point-of-care prescribing decision support |
| Population-scale GWAS (1M samples, 10M variants) | <60 seconds | Interactive hypothesis testing |
| Epigenetic clock computation (353 CpG sites) | <1ms | Real-time biological age estimation |
| Biosurveillance variant detection-to-global-alert | <60 seconds | Pandemic early warning system |
| Base calling throughput (FPGA) | >500 billion inferences/second | Match raw sequencer output rate |
| K-mer HNSW search throughput | >2 million QPS | Sustain read alignment pipeline |

### 5.2 Accuracy Targets

| Metric | Target | Measurement |
|--------|--------|-------------|
| SNV sensitivity | >= 99.999% | True positive rate vs. Genome in a Bottle v4.2.1 truth set |
| SNV specificity | >= 99.99% | 1 - false discovery rate vs. GIAB |
| Indel sensitivity (<50bp) | >= 99.99% | GIAB confident indel regions |
| Structural variant detection (>50bp) | >= 99.5% | GIAB Tier 1 SV truth set |
| Protein structure prediction (LDDT, single domain) | >= 85 | Median LDDT on CASP16 free-modeling targets |
| Pharmacogene star allele concordance | >= 99.9% | Concordance with GeT-RM reference materials |
| Biosurveillance lineage assignment | >= 99.99% | Concordance with Pangolin/Nextclade on known samples |

### 5.3 Scalability Targets

| Dimension | Target | Architecture Component |
|-----------|--------|----------------------|
| Vectors indexed (variant embeddings) | 10 billion | `ruvector-core` HNSW with tiered quantization |
| Genomes in population database | 10 million, scaling to 1 billion | `ruvector-delta-consensus` sharded CRDT |
| Concurrent analysis pipelines | 10,000 | `ruvector-cluster` with Raft coordination |
| Biosurveillance edge nodes | 100,000 | `cognitum-gate-kernel` WASM + delta propagation |
| Protein structures in fold library | 500 million | `ruvector-hyperbolic-hnsw` with PQ compression |
| Temporal methylation data points | 10^12 (28M CpG sites x 1000 time points x ~35,000 samples) | `ruvector-temporal-tensor` tiered storage |

### 5.4 Portability Targets

| Platform | Deployment Model | Primary Use Case |
|----------|-----------------|------------------|
| x86_64 Linux (AVX2/AVX-512) | Server, HPC cluster | Core analysis, population databases |
| ARM64 Linux (NEON) | Edge sequencing nodes, mobile labs | Point-of-care analysis, field biosurveillance |
| Apple Silicon (NEON) | Developer workstations, clinical desktops | Interactive variant review, pharmacogenomics |
| WASM (browser) | Clinical decision support, educational tools | Physician-facing applications, public databases |
| WASM (edge runtime) | Sequencing instrument firmware, IoT sensors | On-instrument base calling, real-time QC |
| FPGA (Xilinx/Intel) | Dedicated acceleration cards | Base calling, transformer inference, VQE simulation |

---

## 6. Architectural Mapping: RuVector Crates to Genomic Pipeline

```
                        RuVector DNA Analyzer Architecture
================================================================================

RAW SIGNAL                    ALIGNMENT                    VARIANT CALLING
----------------             ----------------             ----------------
| Sequencer    |             | K-mer HNSW   |             | GNN Assembly |
| Output       | ---------> | Seed Finding  | ---------> | + Sparse     |
|              |             |              |             | Inference    |
| ruvector-    |             | ruvector-    |             | ruvector-gnn |
| fpga-        |             | core         |             | ruvector-    |
| transformer  |             | (SIMD HNSW)  |             | sparse-inf.  |
----------------             ----------------             ----------------
       |                            |                            |
       v                            v                            v
----------------             ----------------             ----------------
| Signal QC    |             | SW Extension |             | Multi-Layer  |
|              |             | + Scoring    |             | Validation   |
| ruvector-    |             | ruvector-    |             | prime-       |
| nervous-     |             | attention    |             | radiant      |
| system       |             | (flash attn) |             | (coherence)  |
----------------             ----------------             ----------------
                                                                 |
                                                                 v
  ANNOTATION                   POPULATION                  INTERPRETATION
  ----------------             ----------------             ----------------
  | ClinVar,     |             | Pan-Genome   |             | Pharmacogen. |
  | gnomAD,      | <---------- | Graph DB     | ---------> | Resolution   |
  | COSMIC       |             |              |             |              |
  | ruvector-    |             | ruvector-    |             | ruvector-    |
  | hyperbolic-  |             | graph        |             | mincut       |
  | hnsw         |             | ruvector-    |             | ruqu-algo.   |
  ----------------             | delta-       |             ----------------
                               | consensus    |
                               ----------------
                                      |
                                      v
  EPIGENETICS                  BIOSURVEILLANCE             PROTEIN STRUCT
  ----------------             ----------------             ----------------
  | Methylation  |             | Global Edge  |             | Fold Pred.   |
  | Time Series  |             | Network      |             | + Side-Chain |
  |              |             |              |             |              |
  | ruvector-    |             | cognitum-    |             | ruvector-    |
  | temporal-    |             | gate-kernel  |             | attention    |
  | tensor       |             | (WASM)       |             | ruvector-    |
  | ruvector-    |             | ruvector-    |             | fpga-transf. |
  | nervous-sys  |             | delta-cons.  |             | ruqu-algo.   |
  ----------------             ----------------             ----------------

                        CROSS-CUTTING CONCERNS
  ================================================================================
  | sona (Self-Optimizing Neural Architecture) -- adaptive routing & thresholds  |
  | prime-radiant (Coherence Engine) -- structural consistency across all stages  |
  | ruvector-delta-consensus (CRDT) -- distributed state synchronization         |
  | ruvector-raft -- linearizable reads for clinical-grade queries               |
  | ruvector-mincut -- graph partitioning, haplotype phasing, resource allocation|
  ================================================================================
```

---

## 7. Stakeholders

### 7.1 Primary Stakeholders

| Stakeholder | Need | Key Quality Attribute |
|-------------|------|----------------------|
| **Clinical Genomics Laboratories** (e.g., Foundation Medicine, Myriad Genetics, Invitae) | CLIA/CAP-compliant variant calling with rapid turnaround | Accuracy (>99.99% sensitivity), Auditability (witness log), Latency (<1 hour per sample) |
| **Research Hospitals** (e.g., Broad Institute, NIH Clinical Center, NHS Genomic Medicine Service) | Rapid whole-genome analysis for undiagnosed rare disease programs | Latency (<1 second), Sensitivity for novel variants, Multi-omics integration |
| **Pharmaceutical Companies** (e.g., Roche, Pfizer, Novartis) | Population-scale pharmacogenomic screening for clinical trials; companion diagnostic development | Scalability (millions of genomes), Pharmacogene accuracy, Drug interaction prediction |
| **Public Health Agencies** (e.g., CDC, ECDC, WHO) | Real-time genomic surveillance for pandemic preparedness | Latency (<60 seconds detection-to-alert), Global distribution, Byzantine fault tolerance |
| **Space Medicine Programs** (e.g., NASA, ESA, SpaceX) | Autonomous genomic analysis without Earth link; radiation damage assessment | WASM portability, Offline operation, Radiation-induced mutation detection |
| **Agricultural Genomics** (e.g., Bayer Crop Science, Corteva Agriscience) | High-throughput crop and livestock genotyping for breeding programs | Throughput (>10,000 samples/day), Polyploid variant calling, Pangenome graph support |

### 7.2 Secondary Stakeholders

| Stakeholder | Need |
|-------------|------|
| **Bioinformatics tool developers** | Embeddable library (Rust crate) with clean API boundaries |
| **Cloud genomics platforms** (e.g., Terra, DNAnexus, Seven Bridges) | Containerized deployment with horizontal scaling |
| **Direct-to-consumer genomics** (e.g., 23andMe, Ancestry) | Browser-based WASM variant interpretation |
| **Veterinary genomics** | Non-human reference genome support |
| **Forensic genomics** | STR profiling, mixture deconvolution, kinship analysis |
| **Paleogenomics** | Ancient DNA analysis with damage-aware variant calling |

---

## 8. Constraints

### 8.1 Regulatory Constraints

- **FDA 21 CFR Part 820**: Clinical-grade variant calling must comply with Quality System Regulation. This requires full traceability from raw signal to reported variant, implemented via `prime-radiant` witness log with cryptographic hash chains.
- **CLIA/CAP**: Laboratory-developed tests using this platform must be validated against Genome in a Bottle reference materials (HG001-HG007) and GeT-RM pharmacogene reference materials.
- **HIPAA / GDPR**: Patient genomic data must be encrypted at rest and in transit. Memory-safe Rust eliminates an entire class of data exfiltration vulnerabilities. The `ruvector-delta-consensus` CRDT layer must support data sovereignty constraints (certain genomic data cannot leave jurisdictional boundaries).
- **EU IVDR**: In vitro diagnostic regulation requires clinical evidence and conformity assessment for genomic analysis software used in diagnosis.

### 8.2 Technical Constraints

- **Rust edition 2021, MSRV 1.77**: As specified in workspace Cargo.toml. All new crates must maintain this compatibility floor.
- **WASM sandbox**: WASM-compiled components cannot use SIMD intrinsics (SSE/AVX/NEON), file I/O, or multi-threading. Scalar fallback paths and memory-only storage must be maintained for all genomics-critical operations.
- **FPGA bitstream portability**: FPGA designs target Xilinx UltraScale+ and Intel Agilex. The `ruvector-fpga-transformer` abstraction layer (daemon, native_sim, pcie backends) must support both without source changes.
- **Quantum hardware availability**: Near-term quantum advantage requires >1,000 logical qubits for chemistry simulation (VQE) and >10^6 physical qubits for error-corrected Grover's search. The `ruqu-core` classical simulator provides algorithmic validation until hardware matures. All quantum-dependent features must have classical fallback paths.
- **Memory budget**: A clinical sequencing instrument has ~128 GB RAM. The full analysis pipeline for a single 30x WGS sample must operate within 32 GB peak memory, leaving headroom for system processes and concurrent sample analysis.

### 8.3 Assumptions

1. **Sequencing technology convergence**: Both short-read (Illumina) and long-read (ONT, PacBio) platforms will continue to increase throughput and decrease cost, with hybrid sequencing becoming standard for clinical WGS by 2028.
2. **Reference genome evolution**: GRCh38 will be superseded by the T2T-CHM13 + pangenome reference graph. The system must support both linear and graph-based reference representations.
3. **Quantum computing timeline**: Fault-tolerant quantum computers with >1,000 logical qubits will be available for pharmaceutical and research use by 2030-2035. The classical-quantum interface in `ruqu-core` is designed for this transition.
4. **FPGA cost trajectory**: FPGA-as-a-service (AWS F1, Azure Catapult) will make acceleration accessible without capital hardware investment. The `ruvector-fpga-transformer` daemon mode supports remote FPGA access.
5. **Data volume growth**: Global genomic data production will exceed 40 exabytes per year by 2032. Storage and compute architectures must be designed for this scale from inception.

---

## 9. Alternatives Considered

### 9.1 Extend Existing Bioinformatics Frameworks

**Option**: Build on GATK (Java), SAMtools (C), or DeepVariant (Python/TensorFlow).

**Rejected because**:
- Language heterogeneity prevents unified optimization (JVM garbage collection, Python GIL, C memory unsafety).
- No WASM compilation path for edge/browser deployment.
- No integrated vector search, graph database, or quantum computing primitives.
- Retrofitting RuVector's capabilities onto these platforms would require more effort than building genomics on RuVector.

### 9.2 GPU-Only Acceleration (CUDA/ROCm)

**Option**: Build the entire pipeline on GPU-accelerated libraries (CuPy, RAPIDS, PyTorch).

**Rejected because**:
- GPU memory (24-80 GB per card) is insufficient for population-scale databases.
- No deterministic latency guarantees (GPU scheduling is non-deterministic).
- No WASM or edge deployment path.
- Driver and SDK dependencies create portability and maintenance burden.
- RuVector's FPGA path provides deterministic latency; GPU can be added later as an optional accelerator.

### 9.3 Cloud-Native Microservices Architecture

**Option**: Decompose the pipeline into containerized microservices communicating via gRPC/Kafka.

**Rejected because**:
- Network serialization latency (1-10ms per hop) destroys the sub-second pipeline target.
- A single WGS analysis would require >10^9 inter-service messages for per-read operations.
- RuVector's single-process, zero-copy architecture with Rayon parallelism eliminates serialization overhead while maintaining modularity through Rust's crate system.

### 9.4 Build on an Existing Vector Database (Qdrant, Milvus, Weaviate)

**Option**: Use an existing vector database as the substrate and build genomics layers on top.

**Rejected because**:
- No existing vector database has FPGA transformer inference, quantum computing primitives, graph neural networks, spiking neural networks, or temporal tensor compression.
- External database requires IPC overhead for every query.
- No WASM compilation.
- RuVector's `ruvector-core` is already the most capable embedded vector engine available, with proven sub-100us latency.

---

## 10. Consequences

### 10.1 Benefits

1. **Unified computational substrate**: For the first time, all stages of genomic analysis -- from signal processing to clinical interpretation -- share a single memory space, vector representation, and computational framework.
2. **Orders-of-magnitude performance improvement**: Combining SIMD, FPGA, flash attention, and sparse inference techniques produces compound speedups that no single optimization can achieve.
3. **Deploy-anywhere portability**: The same Rust codebase compiles to x86_64, ARM64, WASM, and FPGA bitstreams, enabling genomic analysis from cloud data centers to sequencing instruments to web browsers.
4. **Future-proof quantum integration**: The `ruqu-*` crates provide a quantum algorithm interface that will deliver increasing advantage as quantum hardware matures, without requiring architectural changes.
5. **Regulatory traceability**: The `prime-radiant` coherence engine with cryptographic witness logs provides the audit infrastructure required for clinical-grade genomic analysis.

### 10.2 Risks and Mitigations

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Sub-second genome analysis is not achievable on current hardware | Medium | High | Phased approach: Phase 1 targets 10-second pipeline, Phase 2 targets 1-second with FPGA acceleration |
| Quantum algorithm advantage requires hardware not yet available | High | Medium | All quantum features have classical fallback paths; `ruqu-core` simulator validates algorithms |
| Regulatory approval for novel variant calling algorithms | Medium | High | Validate against GIAB truth sets; pursue FDA breakthrough device designation; maintain GATK-compatible output formats |
| WASM performance gap too large for edge genomics | Low | Medium | Profiling-guided optimization; critical inner loops have WASM-specific implementations |
| Adoption barrier: bioinformatics community is Python-centric | Medium | Medium | Provide Python bindings via PyO3; publish to BioConda; maintain VCF/BAM/CRAM compatibility |
| Data format incompatibility with existing tools | Medium | Low | Full htsjdk-compatible BAM/CRAM/VCF/BCF reader/writer; FHIR Genomics export for EHR integration |

### 10.3 Decision Outcome

We proceed with building the RuVector DNA Analyzer as a new application layer within the RuVector ecosystem, leveraging the full 76-crate stack. Development follows a phased approach:

| Phase | Timeline | Deliverable | Performance Target |
|-------|----------|-------------|-------------------|
| **Phase 1: Foundation** | Q1-Q2 2026 | K-mer embedding in HNSW, variant vector store, basic variant calling | 10-second WGS pipeline |
| **Phase 2: Acceleration** | Q3-Q4 2026 | FPGA base calling, flash attention pileup analysis, GNN assembly | 1-second WGS pipeline |
| **Phase 3: Population** | Q1-Q2 2027 | Distributed variant database, pan-genome graph, population stratification | 10M genomes, sub-second query |
| **Phase 4: Multi-omics** | Q3-Q4 2027 | Epigenetic temporal analysis, protein structure prediction, pharmacogenomics | Full multi-omics integration |
| **Phase 5: Quantum** | 2028+ | VQE drug binding, Grover variant search, QAOA haplotype phasing | Quantum-enhanced accuracy |
| **Phase 6: Global** | 2029+ | Worldwide biosurveillance network, 100K+ edge nodes | 60-second global detection |

---

## 11. References

### Genomics and Bioinformatics

1. Li, H. (2013). "Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM." arXiv:1303.3997.
2. Poplin, R., et al. (2018). "A universal SNP and small-indel variant caller using deep neural networks." Nature Biotechnology, 36(10), 983-987.
3. Van der Auwera, G.A., & O'Connor, B.D. (2020). "Genomics in the Cloud: Using Docker, GATK, and WDL in Terra." O'Reilly Media.
4. Zook, J.M., et al. (2019). "A robust benchmark for detection of germline large deletions and insertions." Nature Biotechnology, 38, 1347-1355.
5. Jumper, J., et al. (2021). "Highly accurate protein structure prediction with AlphaFold." Nature, 596(7873), 583-589.
6. Liao, W.W., et al. (2023). "A draft human pangenome reference." Nature, 617(7960), 312-324.
7. Sangkuhl, K., et al. (2020). "Pharmacogenomics Clinical Annotation Tool (PharmCAT)." Clinical Pharmacology & Therapeutics, 107(1), 203-210.
8. Horvath, S. (2013). "DNA methylation age of human tissues and cell types." Genome Biology, 14(10), R115.

### RuVector Architecture

9. RuVector Team. "ADR-001: Ruvector Core Architecture." /docs/adr/ADR-001-ruvector-core-architecture.md
10. RuVector Team. "ADR-014: Coherence Engine." /docs/adr/ADR-014-coherence-engine.md
11. RuVector Team. "ADR-015: Coherence-Gated Transformer." /docs/adr/ADR-015-coherence-gated-transformer.md
12. RuVector Team. "ADR-017: Temporal Tensor Compression." /docs/adr/ADR-017-temporal-tensor-compression.md
13. RuVector Team. "ADR-QE-001: Quantum Engine Core Architecture." /docs/adr/quantum-engine/ADR-QE-001-quantum-engine-core-architecture.md
14. RuVector Team. "ADR-DB-001: Delta Behavior Core Architecture." /docs/adr/delta-behavior/ADR-DB-001-delta-behavior-core-architecture.md

### Quantum Computing

15. Peruzzo, A., et al. (2014). "A variational eigenvalue solver on a photonic quantum processor." Nature Communications, 5, 4213.
16. Grover, L.K. (1996). "A fast quantum mechanical algorithm for database search." STOC '96, 212-219.
17. Farhi, E., Goldstone, J., & Gutmann, S. (2014). "A Quantum Approximate Optimization Algorithm." arXiv:1411.4028.

---

## Appendix A: Genomic Data Scale Reference

| Entity | Count | Storage per Entity | Total Uncompressed |
|--------|-------|-------------------|-------------------|
| Human genome base pairs | 3.088 x 10^9 | 2 bits | ~773 MB |
| 30x WGS reads (150bp, paired) | ~6 x 10^8 reads | ~300 bytes (FASTQ) | ~180 GB |
| 30x WGS aligned reads (BAM) | ~6 x 10^8 reads | ~200 bytes | ~120 GB |
| Variants per genome (SNV + indel) | ~4.5 x 10^6 | ~200 bytes (VCF) | ~900 MB |
| CpG sites per genome | 2.8 x 10^7 | 4 bytes (methylation fraction) | ~112 MB |
| K-mers (k=31) in human genome | ~3.088 x 10^9 | 8 bytes (2-bit packed + count) | ~24.7 GB |
| Protein-coding genes | ~20,000 | Variable (avg ~1,500 bp CDS) | ~30 MB |
| Known variants (dbSNP) | ~9 x 10^8 | ~200 bytes | ~180 GB |
| gnomAD variant records | ~8 x 10^8 | ~500 bytes (with allele frequencies) | ~400 GB |
| PDB protein structures | ~2.2 x 10^5 | ~1 MB (coordinates) | ~220 GB |
| AlphaFold predicted structures | ~2.14 x 10^8 | ~100 KB (compressed) | ~21 TB |

## Appendix B: K-mer Vector Embedding Design

The core algorithmic innovation of the DNA analyzer's alignment stage is representing k-mers as vectors in a high-dimensional space and using HNSW approximate nearest neighbor search for seed finding.

**Encoding**: Each k-mer (k=31, covering the standard BWA-MEM2 minimum seed length) is encoded as a 128-dimensional f32 vector using a learned embedding function. The embedding is trained to satisfy:

- **Locality**: K-mers differing by 1 substitution have cosine similarity > 0.95.
- **Indel sensitivity**: K-mers sharing a (k-1)-mer prefix or suffix have cosine similarity > 0.85.
- **Separation**: Unrelated k-mers have expected cosine similarity ~0 (random in high dimensions).

**Index structure**: The reference genome's ~3 billion k-mers are indexed in a `ruvector-core` HNSW with:

| Parameter | Value | Rationale |
|-----------|-------|-----------|
| `m` | 48 | Higher connectivity for high recall in SNV-containing regions |
| `ef_construction` | 400 | Aggressive build for maximum graph quality |
| `ef_search` | 200 | Tuned for >99.99% recall of correct seed positions |
| `max_elements` | 4 x 10^9 | Full genome + alternate contigs + decoys |
| Quantization | Scalar (4x compression) | Reduces memory from ~1.5 TB to ~375 GB for full index |

**Search**: For each 150bp read, extract overlapping k-mers (stride 1), batch-query the HNSW index, and chain seeds using the standard minimap2/BWA-MEM chaining algorithm. The HNSW query inherently handles mismatches (approximate search returns neighbors within distance threshold), eliminating the need for explicit seed extension with mismatches.

## Appendix C: Variant Embedding Schema

Each genomic variant is embedded as a 384-dimensional vector (matching `ruvector-core`'s primary benchmark dimension) encoding:

| Dimension Range | Content | Encoding |
|----------------|---------|----------|
| 0-63 | Genomic position | Sinusoidal positional encoding (chromosome + coordinate) |
| 64-127 | Sequence context | Learned embedding of +/- 50bp flanking sequence |
| 128-191 | Allele information | One-hot encoded ref/alt alleles + length + complexity |
| 192-255 | Population frequency | Log-transformed AF across continental groups (AFR, AMR, EAS, EUR, SAS) |
| 256-319 | Functional annotation | CADD, REVEL, SpliceAI, GERP, phyloP scores (normalized) |
| 320-383 | Clinical significance | ClinVar star rating, ACMG classification, gene constraint (pLI, LOEUF) |

This embedding enables a single HNSW query to find variants that are similar across all dimensions simultaneously -- genomically proximal, functionally similar, and clinically related -- a capability that no existing variant annotation tool provides.

---

## Related Decisions

- **ADR-001**: Ruvector Core Architecture (foundation vector engine)
- **ADR-003**: SIMD Optimization Strategy (distance computation)
- **ADR-014**: Coherence Engine (structural consistency)
- **ADR-015**: Coherence-Gated Transformer (attention sparsification)
- **ADR-017**: Temporal Tensor Compression (epigenetic time series)
- **ADR-QE-001**: Quantum Engine Core Architecture (quantum primitives)
- **ADR-DB-001**: Delta Behavior Core Architecture (distributed state)

---

## Revision History

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 0.1 | 2026-02-11 | ruv.io, RuVector Architecture Team | Initial vision and context proposal |
